Skip to content

Trial Summary

A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT- 101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular

Acronym:

AZTEC

ACTRN/NCT /ethics:

NCT03464942

Scientific title:

A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT- 101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular

Sponsor / Cooperative group:

Apollomics

Trial & Patient Characteristics

Cancer TypeLiver, Kidney
Trial TypeTreatment
PhasePhase 1, Phase II
Age Range18+ years
SexBoth
Tumour StreamSolid Tumors
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2017-03-27
Anticipated End Date2021-12-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Amy Hsieh
Recruitment StatusRecruiting